March 29th 2023
Adding avelumab to VEGFR inhibitor axitinib may prolong survival and improve outcomes among patients with recurrent/metastatic adenoid cystic carcinoma.
Single Visit to Multidisciplinary Clinic Improved Efficiency of Head and Neck Cancer Care
October 31st 2017Use of a single-day multidisciplinary clinic visit allowed for more efficient and comprehensive cancer care in a group of patients with head and neck cancer, according to the results of a new study.
Unilateral IMRT Is Effective in Palatine Tonsillar Cancer
October 2nd 2017Use of unilateral intensity-modulated radiotherapy reduced acute toxicities and maintained oncologic outcomes compared with bilateral IMRT in patients with lateralized palatine tonsillar cancer, according to the results of a new study.
FDG-PET/CT With Standardized Reporting Reliable Surveillance for HNSCC
September 30th 2017FDG-PET/CT surveillance using a standardized reporting criteria 12 weeks after concurrent chemoradiotherapy was reliable in patients with locoregionally advanced head and neck squamous cell carcinoma, except in patients with late manifesting residual disease, according to the results of the ECLYPS study.
Vitamin A Derivative Does Not Prevent Second Primary Tumors in Head and Neck Cancer Patients
September 6th 2017Chemoprevention with low-dose 13-Cis retinoic acid, a synthetic vitamin A derivative, did not lower the incidence of second primary tumors in patients with squamous cell cancer of the head and neck.
Nivolumab Approved for Squamous Cell Carcinoma of the Head and Neck
November 14th 2016The US Food and Drug Administration (FDA) in record time has approved nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy.